Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
An erratum to this article was published (Clin Endocrinol (Oxf), Sep 2025 ↗)
Authors' conclusion
T2-signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF-I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
Study context
- Population
- Acromegaly patients treated with pasireotide; 48% women, 50 ± 1.5 years; 93% previously received somatostatin receptor ligands (SRLs)
- Participants
- 81 patients
- Exposure
- T2 magnetic resonance imaging (MRI) iso-hyperintense vs hypointense adenoma signal
- Hyperintensen = 56
- Hypointensen = 25reference
- Outcome
- Hormonal response (IGF-1 normalization) and significant tumour shrinkage (volume reduction ≥25%) by baseline T2 MRI signal
- Follow-up
- 6 and 12 months
Methodological detailsmulticentre, real-life clinical practice
- Multicentre
- Real-life clinical practice
Main finding
As reported in the abstract
IGF-1 normalization · 12 months
Overall IGF-1 normalization
42 of 73
58%
Overall growth hormone (GH) and IGF-1 normalization
37%
Observational data: associations, not effects.
Further findings
Significant tumour volume shrinkage (≥25%)
- Significant tumour volume shrinkage (≥25%) — Overall significant shrinkage
- 19/51 (37%)
Original publication
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf). Published 8 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →